ArticleMicrobiology spectrum2022
Antimicrobial Peptide Combination Can Hinder Resistance Evolution.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Article
- Antimicrobial Potential of Defensin-DerivedInternational journal of molecular sciences · 2026Article
- Design of a multimodal synthetic peptide antibiotic derived from human cathelicidin.Cell biomaterials · 2026Article
- Combined application of Vancomycin and Levofloxacin potentiates the antimicrobial activity against MRSA: a response surface methodology-based study.Folia microbiologica · 2026Article
- The Antimicrobial Peptide C14R Is Active Against All Pathogenic Species of the ESKAPE Group.Antibiotics (Basel, Switzerland) · 2026Article
- From Host-Derived Pressures to the Environmental Anti-Antimicrobial Peptides Resistome: Mechanisms, Reservoirs and Implications for Therapeutic Peptide Design.Marine drugs · 2026Review
- Antimicrobial Peptide Nanoassemblies: Design, Response Mechanisms, and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
- Short peptide 803sp inhibits the inflammatory response induced byFrontiers in cellular and infection microbiology · 2026Article
- Creation of New Antimicrobial Peptides 3: Research Promises and Shortcomings.International journal of molecular sciences · 2025Article
- Antimicrobial peptides: structure, functions and translational applications.Nature reviews. Microbiology · 2025Review
- Characteristics and Potential of KSL, KSL-W, and Dadapin-1 Antimicrobial Peptides for Preventing Infections of Orthopedic Prosthetic Devices: Identifying the Most Robust Candidate.International journal of molecular sciences · 2025Article
- Combinatorial Effects of CPP-Modified Antimicrobial Peptides: Synergistic and Additive Interactions Against Pathogenic Bacteria.International journal of molecular sciences · 2025Article
- Uncovering the genetic basis ofiScience · 2025Article
- The Study of Antistaphylococcal Potential of Omiganan and Retro-Omiganan Under Flow Conditions.Probiotics and antimicrobial proteins · 2025Article
- Random antimicrobial peptide mixtures as non-antibiotic antimicrobial agents for cultured meat industry.Food chemistry. Molecular sciences · 2025Article
- Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics.PloS one · 2025Article
- Exploring the antimicrobial potential of crude peptide extracts fromPharmaceutical biology · 2024Article
- Designing Analogs of SAAP-148 with Enhanced Antimicrobial and Anti-LPS Activities.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant microbial pathogens are becoming a major threat to human health. Therefore, there is an urgent need to develop new alternatives to conventional antibiotics. One such promising alternative is antimicrobial peptides (AMPs), which are produced by virtually all organisms and typically inhibit bacteria via membrane disruption. However, previous studies demonstrated that bacteria can rapidly develop AMP resistance. Here, we study whether combination therapy, known to be able to inhibit the evolution of resistance to conventional antibiotics, can also hinder the evolution of AMP resistance. To do so, we evolved the opportunistic pathogen Staphylococcus aureus in the presence of individual AMPs, AMP pairs, and a combinatorial antimicrobial peptide library. Treatment with some AMP pairs indeed hindered the evolution of resistance compared with individual AMPs. In particular, resistance to pairs was delayed when resistance to the individual AMPs came at a cost of impaired bacterial growth and did not confer cross-resistance to other tested AMPs. The lowest level of resistance evolved during treatment with the combinatorial antimicrobial peptide library termed random antimicrobial peptide mixture, which contains more than a million different peptides. A better understanding of how AMP combinations affect the evolution of resistance is a crucial step in order to design "resistant proof" AMP cocktails that will offer a sustainable treatment option for antibiotic-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.